June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Intravitreal Aflibercept for the Treatment of Diabetic Macular Edema: Evaluating the Impact on Diabetic Retinopathy
Author Affiliations & Notes
  • Paul Mitchell
    Ophthalmology, University of Sydney, Sydney, NSW, Australia
  • Mark C Gillies
    Ophthalmology, University of Sydney, Sydney, NSW, Australia
  • Michael Larsen
    University of Copenhagen, Copenhagen, Denmark
  • Giovanni Staurenghi
    University of Milan, Milan, Italy
  • Frank G Holz
    University of Bonn, Bonn, Germany
  • Todd A Katz
    Bayer HealthCare Pharmaceuticals, Whippany, NJ
  • Chengxing Lu
    Bayer HealthCare Pharmaceuticals, Whippany, NJ
  • Christiane Ahlers
    Bayer Pharma AG, Berlin, Germany
  • Carola Metzig
    Bayer Pharma AG, Berlin, Germany
  • Oliver Zeitz
    Bayer Pharma AG, Berlin, Germany
  • Footnotes
    Commercial Relationships Paul Mitchell, Abbott (C), Abbott (R), Allergan (C), Allergan (R), Bayer (C), Bayer (R), Novartis (C), Novartis (R); Mark Gillies, Allergan (C), Allergan (R), Bayer (C), Bayer (R), Novartis (C), Novartis (R), Pfizer (C), Pfizer (R); Michael Larsen, Allergan (C), Allergan (F), Astra Zeneca (C), Glaxo Smith Kline (C), Glaxo Smith Kline (F), Novartis (C), Novartis (F), Novo Nordisk (C), Roche (C), Roche (F); Giovanni Staurenghi, Alcon (C), Allergan (C), Bayer (C), Bayer (R), Genetech (C), Heidelberg Engineering (C), Novartis (C), Ocular Instruments Inc (P), OD-OS (C), QLT (C), Roche (C), Zeiss (R); Frank Holz, Alcon (C), Bayer (C), Bayer (F), Genentech (C), Genentech (F), Novartis (C), Novartis (F), Roche (C), Roche (F); Todd Katz, Bayer (E); Chengxing Lu, Bayer (E); Christiane Ahlers, Bayer (E); Carola Metzig, Bayer (E); Oliver Zeitz, Bayer (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 3146. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Paul Mitchell, Mark C Gillies, Michael Larsen, Giovanni Staurenghi, Frank G Holz, Todd A Katz, Chengxing Lu, Christiane Ahlers, Carola Metzig, Oliver Zeitz, ; Intravitreal Aflibercept for the Treatment of Diabetic Macular Edema: Evaluating the Impact on Diabetic Retinopathy. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):3146.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To evaluate the impact of intravitreal aflibercept injection (IAI) on diabetic retinopathy severity in patients with diabetic macular edema (DME).

Methods: The VIVID-DME and VISTA-DME trials evaluated IAI vs. laser for DME. Patients were randomized to IAI 2mg every 4 weeks + sham laser, IAI 2mg every 8 weeks (after 5 initial monthly doses) + sham laser, or laser + sham injections. The primary endpoint was change from baseline (BL) in BCVA at week 52 (W52). The proportion of patients with a ≥2-step improvement from BL on the diabetic retinopathy severity scale (DRSS) was a secondary end point. The current exploratory analyses assessed additional changes in the DRSS, as well as the development of proliferative diabetic retinopathy (PDR) up to W52. Patients were considered to have developed PDR if BL DRSS score was <61 and there was at least 1 post-BL DRSS score ≥61. As the DRSS was assessed only at BL, W24 and W52, use of panretinal photocoagulation (PRP) was also evaluated as a proxy for PDR development. Pooled IAI data are reported.

Results: The proportion of patients receiving IAI vs. laser with a ≥2-step improvement in DRSS at W52 was 30.5% vs. 7.5% (VIVID-DME) and 31.5% vs. 14.3% (VISTA-DME); the proportion with a ≥3-step improvement at W52 was 3.0% vs. 0.0% (VIVID-DME) and 14.7% vs. 5.2% (VISTA-DME). The proportion of patients receiving IAI vs. laser who developed PDR through W52 was 0.7% vs. 5.3% (VIVID-DME) and 2.6% vs. 9.1% (VISTA-DME); when the data were integrated, the respective proportions were 1.7% vs. 7.3% (P=0.0001). The proportion of patients receiving IAI vs. laser who received PRP through W52 was 1.1% vs. 3.0% (VIVID-DME) and 0.7% vs. 3.9% (VISTA-DME); when the data were integrated, the respective proportions were 0.9% vs. 3.5% (P=0.0099). It is possible that mild cases of PDR may not have led to PRP use; hence, the difference proportions in the 2 analyses. Overall, the most common ocular serious AEs in IAI-treated patients were cataract (VIVID-DME, 0.7%) and vitreous hemorrhage (VISTA-DME, 0.7%).

Conclusions: These findings from the initial 52 weeks of the VIVID-DME and VISTA-DME studies demonstrate benefits of IAI over laser in terms of diabetic retinopathy outcomes. These data further support the concept that IAI has a beneficial impact not only on DME, but also on the underlying diabetic retinopathy.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×